

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Brexucabtagene autoleucl for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Mantle cell lymphoma is more prevalent in men than women. No other equalities issues were identified during scoping.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This does not constitute an equalities issue that needs to be addressed by the committee in its evaluation of the technology.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the draft scope is required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Associate Director:** Emily Crowe

**Date:** 08/11/2024